Active Not Recruiting
PHASE4
INTERVENTIONAL
NCT05433584
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Antihyperglycemic medication
Type:
DRUG
Description:
As prescribed
Primary Outcomes
Measure:
Change from Baseline in Hemoglobin A1c (HbA1c)
TimeFrame:
Baseline, Week 104
Description:
Trial Information
NCT ID
NCT05433584
Status
Active Not Recruiting
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025